We are live on ! Find out more
SHPH icon

Shuttle Pharmaceuticals
SHPH

4 hedge funds and large institutions have $26.8K invested in Shuttle Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

56% less capital invested

Capital invested by funds: $61.5K → $26.8K (-$34.7K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$842

Top Sellers

Rank Fund Capital Flow
1
SG
StoneX Group
New York
-$22.8K
2
Renaissance Technologies
Renaissance Technologies
New York
-$5.05K
3
VF
Virtu Financial
New York
-$4.21K

SHPH Hedge Fund Activity: Q1 2024 in Review

4 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q1 2024, worth a combined $26.8K — down 56% from $61.5K a quarter earlier.

Fund positioning in SHPH was balanced in Q1 2024: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $842. The largest seller was StoneX Group, exiting entirely with an estimated $22.8K sold.

  • 4 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $26.8K of Shuttle Pharmaceuticals stock for Q1 2024, down 56% quarter-over-quarter.
  • 1 fund opened new Shuttle Pharmaceuticals positions in Q1 2024 and 1 closed out, a net change of 0 holders.
  • The largest Shuttle Pharmaceuticals buyer in Q1 2024 was UBS Group, an estimated $842 added.
  • The largest Shuttle Pharmaceuticals seller in Q1 2024 was StoneX Group, an estimated $22.8K sold.

Based on aggregated 13F filings for Q1 2024.